指南与共识系统性红斑狼疮

基于2025 EULAR推荐构建并验证狼疮肾炎质量指标:依从性趋势与临床结局关联

Development and validation of quality indicators for lupus nephritis, based on the 2025 EULAR recommendations: adherence trends and impact on clinical outcomes.
指南 / 共识 · Ann Rheum Dis · 2026-07-10

本研究基于2025 EULAR关于系统性红斑狼疮伴肾脏受累的推荐,采用改良RAND/UCLA适宜性方法经两轮23名专家投票制定狼疮肾炎质量指标(QI),并在单中心130例当代狼疮肾炎队列中评估依从性与结局的关联。共形成17项QI,高患者层面依从性与较低的损伤累积风险相关(OR 0.29,95%CI 0.13-0.62),与肾脏 flare 的关联未达统计学显著。

要点

  • 共制定17项QI,覆盖诊断、治疗、监测和妊娠4个领域。
  • 初始联合免疫抑制治疗依从率低(10.7%),反映推荐发布前实践。
  • 高患者层面依从性与较低损伤累积风险相关(OR 0.29,95%CI 0.13-0.62)。

核心结论

  • 基于2025 EULAR推荐的狼疮肾炎QI可作为落实推荐的 structured framework,高依从性与较低损伤累积相关,但需在多中心验证。

研究设计与样本

  • 采用改良RAND/UCLA适宜性方法,经2轮23名专家投票制定核心QI集,并在单中心当代狼疮肾炎队列(n=130)中评估依从性与结局关联。

主要发现

  • 共制定17项QI,覆盖诊断、治疗、监测和妊娠4个领域。
  • 肾脏活检、羟氯喹使用、维持免疫抑制、持续或复发疾病中换药、RAS抑制剂使用、肾移植前缓解及妊娠相关QI观察到高依从性。
  • 初始联合免疫抑制治疗依从率低(10.7%)。
  • 高患者层面依从性与较低损伤累积风险相关(OR 0.29,95%CI 0.13-0.62)。
  • 高依从性与较少肾脏 flare 相关,但未达统计学显著。

关键数值与推荐

  • 高依从性定义为≥80%。
  • 初始联合免疫抑制治疗依从率为10.7%。
  • 高患者层面依从性与损伤累积的OR为0.29(95%CI 0.13-0.62)。

临床怎么用

  • QI可用于结构化评估和落实2025 EULAR狼疮肾炎推荐。
  • 关注初始联合免疫抑制治疗等低依从环节,可能有助于改善结局。

局限性

  • 依从性与结局关联来自单中心三级中心队列,需在多样化临床环境中验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: This study aimed to develop a set of quality indicators (QIs) based on the 2025 European Alliance of Associations for Rheumatology (EULAR) recommendations for systemic lupus erythematosus with kidney involvement and explore their association with disease outcomes. METHODS: A modified Research and Development and University of California, Los Angeles appropriateness method was used. In 2 voting rounds, 23 experts rated candidate QIs for validity and feasibility. Median ratings and agreement were calculated, leading to a core QI set. Adherence to recommended care from healthcare providers was assessed at both QI and patient levels in a single tertiary centre contemporary lupus nephritis (LN) cohort (n = 130). High adherence was defined as ≥80%. Associations between adherence to QIs, damage accrual, and renal flares were explored. RESULTS: A total of 17 QIs were developed across 4 domains: diagnosis, treatment, monitoring, and pregnancy. High adherence was observed for kidney biopsy, hydroxychloroquine use, maintenance immunosuppression, therapy switching in persistent or relapsing disease, renin-angiotensin system inhibitor use, remission before kidney transplantation, and pregnancy-related QIs. Combination immunosuppressive therapy as initial treatment had low adherence (10.7%), reflecting practice patterns preceding publication of the recommendations. High per-patient adherence was associated with lower odds of damage accrual (increase in Systemic Lupus International Collaborating Clinic Damage Index; odds ratio: 0.29, 95% CI: 0.13-0.62) and fewer renal flares, although the latter association was not statistically significant. CONCLUSIONS: These QIs may serve as a structured framework for implementing the 2025 EULAR recommendations for LN. Higher adherence was associated with reduced damage accrual in a tertiary centre cohort, but results need validation in diverse clinical settings.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Akat ΕO, Kostopoulou M, Katechis S, et al. Development and validation of quality indicators for lupus nephritis, based on the 2025 EULAR recommendations: adherence trends and impact on clinical outcomes. Ann Rheum Dis. 2026. PMID: 42431783. doi:10.1016/j.ard.2026.05.030

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。